Gerald Schulman
Last active: 2/26/2014

  1. Hemodialysis: core curriculum 2014. Golper TA, Fissell R, Fissell WH, Hartle PM, Sanders ML, Schulman G (2014) Am J Kidney Dis 63(1): 153-63
    › Citation · 24268927 (PubMed) · PMC4276338 (PubMed Central)
  2. AST-120 for the management of progression of chronic kidney disease. Schulman G, Vanholder R, Niwa T (2014) Int J Nephrol Renovasc Dis : 49-56
    › Citation · 24501542 (PubMed) · PMC3912158 (PubMed Central)
  3. Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis. Umanath K, Sika M, Niecestro R, Connelly C, Schulman G, Koury MJ, Lewis JB, Dwyer JP, Collaborative Study Group (2013) Hemodial Int 17(1): 67-74
    › Citation · 22702490 (PubMed)
  4. In-center thrombolysis for clotted AV access: a cohort review. Umanath K, Morrison RS, Christopher Wilbeck J, Schulman G, Bream P, Dwyer JP (2013) Semin Dial 26(1): 124-9
    › Citation · 22784240 (PubMed)
  5. Effects of 6-times-weekly versus 3-times-weekly hemodialysis on depressive symptoms and self-reported mental health: Frequent Hemodialysis Network (FHN) Trials. Unruh ML, Larive B, Chertow GM, Eggers PW, Garg AX, Gassman J, Tarallo M, Finkelstein FO, Kimmel PL, FHN Trials Group (2013) Am J Kidney Dis 61(5): 748-58
    › Citation · 23332990 (PubMed) · PMC4552179 (PubMed Central)
  6. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial. Dwyer JP, Sika M, Schulman G, Chang IJ, Anger M, Smith M, Kaplan M, Zeig S, Koury MJ, Blumenthal SS, Lewis JB, Collaborative Study Group (2013) Am J Kidney Dis 61(5): 759-66
    › Citation · 23369827 (PubMed)
  7. APOL1 risk variants, race, and progression of chronic kidney disease. Parsa A, Kao WH, Xie D, Astor BC, Li M, Hsu CY, Feldman HI, Parekh RS, Kusek JW, Greene TH, Fink JC, Anderson AH, Choi MJ, Wright JT, Lash JP, Freedman BI, Ojo A, Winkler CA, Raj DS, Kopp JB, He J, Jensvold NG, Tao K, Lipkowitz MS, Appel LJ, AASK Study Investigators, CRIC Study Investigators (2013) N Engl J Med 369(23): 2183-96
    › Citation · 24206458 (PubMed) · PMC3969022 (PubMed Central)
  8. Tolvaptan in patients with autosomal dominant polycystic kidney disease. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS, TEMPO 3:4 Trial Investigators (2012) N Engl J Med 367(25): 2407-18
    › Citation · 23121377 (PubMed) · PMC3760207 (PubMed Central)
  9. The mitochondrial complex I activity is reduced in cells with impaired cystic fibrosis transmembrane conductance regulator (CFTR) function. Valdivieso AG, Clauzure M, Marín MC, Taminelli GL, Massip Copiz MM, Sánchez F, Schulman G, Teiber ML, Santa-Coloma TA (2012) PLoS One 7(11): e48059
    › Citation · 23185247 (PubMed) · PMC3504030 (PubMed Central)
  10. Challenges to enrollment and randomization of the Frequent Hemodialysis Network (FHN) Daily Trial. Sergeyeva O, Gorodetskaya I, Ramos R, Schiller BM, Larive B, Raimann JG, Ting GO, Eggers PW, Chertow GM, Levin NW, Frequent Hemodialysis Network Trials Group (2012) J Nephrol 25(3): 302-9
    › Citation · 22505248 (PubMed)